UBX - Unity Biotechnology, Inc.
| Previous Close | 6.18 |
| Open | 6.13 |
| Bid | 3.15 x 1200 |
| Ask | 7.50 x 1100 |
| Day's Range | 6.00 - 6.30 |
| 52 Week Range | 6.00 - 24.56 |
| Volume | 147,230 |
| Avg. Volume | 285,868 |
| Market Cap | 267.427M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.97 |
| Earnings Date | Aug 7, 2019 - Aug 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.60 |
- GlobeNewswire
UNITY Biotechnology, Inc. Reports Second Quarter 2019 Financial Results and Program Updates
SAN FRANCISCO, Aug. 07, 2019 -- UNITY Biotechnology, Inc. (UNITY) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.
- GlobeNewswire
UNITY Biotechnology, Inc. Announces Plan for Phase 2 Clinical Study of UBX0101 in Osteoarthritis of the Knee
UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced details for the planned Phase 2 study of UBX0101 in patients with osteoarthritis (OA) of the knee. "In June, we announced promising results from our Phase 1 study of UBX0101 in patients with OA of the knee showing that our senolytic molecule had a dose-dependent response across multiple clinical endpoints," said Keith Leonard, chairman and chief executive officer of UNITY. “We look forward to substantiating the promising results we observed in Phase 1 in a larger Phase 2 study.
- GlobeNewswire
UNITY Biotechnology, Inc. To Announce Second Quarter 2019 Financial Results
SAN FRANCISCO, July 30, 2019 -- UNITY Biotechnology, Inc. (UNITY) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.
- Motley Fool
Here's Why Unity Biotechnology Dropped as Much as 20.4% Today
The longevity-focused biopharma delivered mixed results in its first clinical trial in humans.
- GlobeNewswire
UNITY Biotechnology Reports Promising Topline Data from Phase 1 First-in-human Study of UBX0101 in Patients with Osteoarthritis of the Knee
SAN FRANCISCO, June 18, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ: UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced promising results from its first-in-human Phase 1 study of UBX0101 in patients with moderate to severe osteoarthritis (OA) of the knee. Improvement in several clinical measures, including pain, function, as well as modulation of certain senescence-associated secretory phenotype (SASP) factors and disease-related biomarkers was observed after a single dose of UBX0101. “New treatments for OA are desperately needed, especially an intervention that targets the biology of the condition that includes cell senescence,” said Richard F. Loeser, Jr., M.D., Director, UNC Thurston Arthritis Research Center Herman and Louise Smith Distinguished Professor of Medicine, Division of Rheumatology, Allergy & Immunology.
- Benzinga
The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 29) Chiasma Inc (NASDAQ: CHMA ) Soliton Inc (NASDAQ: SOLY ...
- GlobeNewswire
UNITY Biotechnology, Inc. and UCSF Enter Exclusive License Agreement on alpha-Klotho Protein for the Treatment of Age-Related Cognitive Decline
UNITY Biotechnology, Inc. (“UNITY”) (UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, and UC San Francisco (UCSF) today announced that UNITY executed an exclusive, worldwide license to UCSF intellectual property relating to the alpha-Klotho protein, a circulating factor associated with improved cognitive performance.
- GlobeNewswire
UNITY Biotechnology, Inc. to Present at Upcoming Investor Conferences
SAN FRANCISCO, May 23, 2019 -- UNITY Biotechnology, Inc. (“UNITY”) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.
- Zacks
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
- Zacks
5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon
Trade-war resistant stocks such as biotechs would be the first to benefit from a relief rally.
- Simply Wall St.
Do Directors Own Unity Biotechnology, Inc. (NASDAQ:UBX) Shares?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- GlobeNewswire
UNITY Biotechnology, Inc. Reports First Quarter 2019 Financial Results
SAN FRANCISCO, May 08, 2019 -- UNITY Biotechnology, Inc. (“UNITY”) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.
- GlobeNewswire
UNITY Biotechnology, Inc. to Announce First Quarter 2019 Financial Results
SAN FRANCISCO, April 29, 2019 -- UNITY Biotechnology, Inc. (“UNITY”) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.
- GlobeNewswire
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Program Updates
SAN FRANCISCO, March 06, 2019 -- UNITY Biotechnology, Inc. (UNITY) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.
- GlobeNewswire
UNITY Biotechnology, Inc. to Participate in the Cowen 39th Annual Health Care Conference
SAN FRANCISCO, March 04, 2019 -- UNITY Biotechnology, Inc. (“UNITY”) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.
- GlobeNewswire
CORRECTING and REPLACING -- UNITY Biotechnology, Inc. to Announce Fourth Quarter and Full Year 2018 Financial Results
SAN FRANCISCO, Feb. 27, 2019 -- In a release issued under the same headline on February 25th by UNITY Biotechnology, Inc. , please note that in the first paragraph.
- GlobeNewswire
UNITY Biotechnology, Inc. to Announce Fourth Quarter and Full Year 2018 Financial Results
SAN FRANCISCO, Feb. 25, 2019 -- UNITY Biotechnology, Inc. (UNITY) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.
- Benzinga
The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 22) Veracyte Inc (NASDAQ: VCYT ) Down In The Dumps (Biotech ...
- GlobeNewswire
UNITY Biotechnology Expands Ongoing UBX0101 Phase 1 Study to Further Evaluate SASP Factors in Osteoarthritis of the Knee
UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced further expansion of the Phase 1 study of UBX0101 in patients with moderate to severe osteoarthritis (OA) of the knee with a cohort of an additional 24 patients at the highest evaluated dose (4mg) (Part B). Part B is intended to supplement the initial Phase 1 trial (Part A) by further evaluating the impact of UBX0101 on specific pro-inflammatory and extracellular matrix modifying factors within the Senescence-Associated Secretory Phenotype (SASP). To measure SASP factors, an adequate volume of synovial fluid is required in the knee joint capsule to collect a sample.
- PR Newswire
Ascentage Pharma Announces New License with Unity Biotechnology
ROCKVILLE, Md. and HONG KONG , Jan. 8, 2019 /PRNewswire/ -- Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other ...
- GlobeNewswire
UNITY Biotechnology Announces Completion of UBX1967 License and Advance into IND-Enabling Studies for Age-Related Diseases of the Eye
UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend human healthspan by slowing, halting or reversing diseases of aging, today announced it has selected UBX1967 as the lead development candidate in the ophthalmology pipeline for advancement into studies to enable an Investigational New Drug (IND) application and executed the compound license agreement for the compound with Ascentage Pharma Group Corp Limited (“Ascentage Pharma”) under a previously agreed compound library agreement. UBX1967 is being evaluated in a range of age-related diseases of the eye, including neovascular age-related macular degeneration, proliferative diabetic retinopathy and diabetic macular edema.
- American City Business Journals
This year's Bay Area IPO batch remains up 44% despite market turbulence
Stocks from eight of the 34 companies from the region that went public this year are now below their IPO price. Six others are trading at double or more where they started.
- Zacks
UNITY (UBX) Soars: Stock Adds 5.1% in Session
UNITY (UBX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- GlobeNewswire
UNITY Biotechnology, Inc. Appoints Margo Roberts Ph.D. to Board of Directors
SAN FRANCISCO, Dec. 04, 2018 -- UNITY Biotechnology, Inc. (“UNITY”) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.
- Benzinga
The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 3) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
